NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- __________________ WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024. Lifecore describes itself as an "integrated contract development and manufacturing organization in the U.S. and internationally." A class action lawsuit has already been filed. If you wish to serve as lead plainti ...

NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024. Lifecore describes itself as an "integrated contract development and manufacturing organization in the U.S. and internationally." A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Co ...

LOS ANGELES, Aug. 1, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Per ...

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), have until September 27, 2024 to seek appointment as lead plaintiff of the Lifecore Biomedical class action lawsuit. Captioned Carew v. Lifecore Biomedical, Inc., No. 24-cv-03028 (D. Minn.), the Lifecore Biomedical class action lawsuit charges Lifecore ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) in the United States District Court for the District of Minnesota on behalf of all persons and entities who purchased or otherwise acquired Lifecore securities between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"). Investo ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Lifecore Biomedical, Inc. ("Lifecore") (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"). For more information, submit a form at Lifecore Biomedical, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@ber ...

Core Points - A shareholder class action lawsuit has been filed against Lifecore Biomedical, Inc. alleging that the company made materially false and misleading statements regarding its business and operations [3] - The lawsuit claims that Lifecore had deficient internal controls over financial reporting, leading to inaccurate financial statements that would need to be restated [3] - It is alleged that Lifecore's remediation efforts regarding these deficiencies were ineffective, impairing the company's ability to file periodic reports with the SEC in compliance with NASDAQ requirements [3] - The lawsuit asserts that Lifecore's financial position and prospects were materially overstated as a result of these issues [3] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is September 27, 2024 [4]

Core Viewpoint - A securities class action lawsuit has been filed against Lifecore Biomedical, Inc. for allegedly making materially false and misleading statements regarding its financial reporting and internal controls [2][4]. Group 1: Allegations of Misconduct - The lawsuit claims that Lifecore failed to disclose deficiencies in its internal controls over financial reporting [1][4]. - It is alleged that Lifecore issued inaccurate financial statements that would require restatement due to these deficiencies [1][4]. - The company's remediation efforts regarding these internal control deficiencies were deemed ineffective [1][4]. - Lifecore's inability to file periodic reports with the SEC in a timely manner is also highlighted as a significant issue [1][4]. - The lawsuit asserts that the company's financial position and prospects were materially overstated as a result of these issues [1][4]. Group 2: Impact on Stock Price - Following the revelation of these issues, Lifecore's stock price dropped by $2.18 per share, representing a decline of 30.32%, closing at $5.01 per share on March 20, 2024 [6]. Group 3: Class Action Details - The class action lawsuit covers all individuals or entities that purchased Lifecore securities between October 7, 2020, and March 19, 2024 [2]. - Investors are encouraged to contact the law firm representing the class action before the lead plaintiff motion deadline on September 27, 2024 [5].

If you suffered substantial losses and wish to serve as lead plaintiff of the Lifecore Biomedical class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449- 4900 or via e-mail at info@rgrdlaw.com. The Lifecore Biomedical class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Lifecore Biomedical maintained defi ...

About Lifecore Biomedical The RSU award will vest and be settled as to 25,000 shares of the RSU on May 20, 2024 and as to 100,000 shares of the RSU on each of the first five anniversaries of May 20, 2024 and is governed by a Restricted Stock Unit Award Agreement and the Inducement Plan. The PSU award will vest, if at all, based upon the Performance Price achievement within the five year performance period as compared to a range of ten prices from $7.50 per share to $35.00 per share. The Performance Price is ...